Top

Published in:

01-06-2003 | Review Article

Consensus on Drug Treatment, Definition and Diagnosis for Insomnia

Authors: Dr E. Estivill, A. Bové, D. García-Borreguero, J. Gibert, J. Paniagua, G. Pin, F. J. Puertas, R. Cilveti

Published in: Clinical Drug Investigation | Issue 6/2003

Abstract

Thirty-four experts and a literature supervisor got together in order to reach a ‘consensus’ regarding the definition, diagnosis and pharmacological treatment of insomnia. Insomnia is a subjective perception of dissatisfaction with the amount and/or quality of sleep. It includes difficulty in initiating or maintaining sleep or early awakening with inability to fall asleep again. It is associated with complaints of non-restorative sleep and dysfunction of diurnal alertness, energy, cognitive function, behaviour or emotional state, with a decrease in quality of life. The diagnosis is based on clinical and sleep history, physical examination and additional tests, although polysomnography is not routinely indicated. Therapy should include treatment of the underlying causes, cognitive and behavioural measures and drug treatment. Hypnotic therapy can be prescribed from the onset of insomnia and non-benzodiazepine selective agonists of the GABA-A receptor complex are the drugs of first choice. It is recommended that hypnotic treatment be maintained in cases where withdrawal impairs the patient’s quality of life and when all other therapeutic measures have failed. Experience suggests that intermittent treatment is better than continuous therapy. The available data do not confirm safety of hypnotics in pregnancy, lactation and childhood insomnia. Benzodiazepines are not indicated in decompensated chronic pulmonary disease but no significant adverse effects on respiratory function have been reported with zolpidem and zopiclone in stable mild to moderate chronic obstructive pulmonary disease and in treated obstructive sleep apnoea syndrome. Data for zaleplon are inconclusive. If the patient recovers subjective control over the sleep process, gradual discontinuation of hypnotic treatment can be considered.

Gallup Organization. Sleep in America. Princeton (NJ): Gallup Organization, 1995

Hohagen F, Rink K, Schramm E, et al. Prevalence and treatment of insomnia in general-practice: a longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993; 242: 325–36

Quera-Salva MA, Orluc A, Goldenberg F. Insomnia and the use of hypnotic: study of a French population. Sleep 1991; 14: 386–91PubMed

Sateia MJ, Doghramji K, Hauri PJ, et al. Evaluation of chronic insomnia. Sleep 2000; 23(2): 243–302PubMed

Jenkins CD, Stanton BA, Niemcryk SJ, et al. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988; 41(4): 313–21PubMed

Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998; 158(10): 1099–107PubMed

Carney RM, Freedland KE, Jaffe AS. Insomnia and depression prior to myocardial infarction. Psychosom Med 1990; 52(6): 603–9PubMed

Kripke DF, Simons RN, Garfinkel L, et al. Short and long sleep and sleeping pills: is increased mortality associated? Arch Gen Psychiatry 1979; 36(1): 103–16PubMed

Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. Sleep 1983; 6(2): 102–7PubMed

10.

Zammit GK. Quality of life in people with insomnia. Sleep 1999; 1(22 Suppl. 2): S379–85

11.

Chevalier H. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 1999; 13(4 Suppl. 1): S21–4PubMed

12.

Hajak G. Insomnia in primary care. Sleep; Suppl 3: S54-S63, 23

13.

Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey: II. Sleep 1999; 22 Suppl. 2: S354–8PubMed

14.

Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262(11): 1479–84PubMed

15.

Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16(5): 873–97PubMed

16.

Van de Ven AH, Delbecq AL. The nominal group as a research instrument for exploratory health studies. Am J Public Health 1972; 632: 337–42

17.

Delbecq AL, Van deVen AH. A group process model for problem identification and program planning. J Appl Behav Sci 1971; 7: 467–92

18.

Pill J. The Delphi method: substance, context, a critique and an annotated bibliography. Socio Econ Plan Sci 1971; 3: 57–71

19.

Linstone HA, Turoff M. The Delphi method: techniques and applications. Addison-Wesley Publishing Co. Boston, MA. 1975

20.

International Consensus Conference on Insomnia, Versailles, France. October 1996. (WHO Doc.: MSA/MND/98.2). Sleep 1999; 22 (s3): s413–52

21.

Diccionario Manual e Ilustrado de la Lengua Española. 4^a ed. S.A. Madrid: Espasa-Calpe, 1989

22.

Roth T, Hajak G, Üstün TB. Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 2001; 55(1): 42–52PubMed

23.

ASDA. International Classification of Sleep Disorders: diagnostic and coding manual. In: Thorpy MJ, editor. Diagnostic classification steering committee. Rochester (MN): American Sleep Disorders Association, 1990

24.

Holbrook AM, Crowter R, Lotter A, et al. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. CMAJ 2000; 16(2): 216–20

25.

Parkes JD. Sleep an its disorders. In: Walton J, editor. Major problems in neurology. Vol. 14. London: WB Saunders, 1985

26.

Roehrs T, Pedrosi B, Rosenthal L, et al. Hypnotic self administration and dose escalation. Psychopharmacology 1996; 127: 150–4PubMed

27.

Roth T, Roehrs T, Costa e Silva JA, et al. Public health and insomnia: consensus statement regarding its status and needs for future actions. Sleep 1999; 22 Suppl. 3: 417–20

28.

Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999; 22(3): 371–5PubMed

29.

Chesson A, Hartse K, McDowell W, et al. Practice parameters for the evaluation of chronic insomnia. Sleep 2000; 23(2): 237–41PubMed

30.

National Heart Lung and Blood Institute Working Group on Insomnia. Insomnia: assessment and management in primary care. Am Fam Physician 1999; 59(11): 3029–38

31.

Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med 1997; 336(5): 341–6PubMed

32.

Mitler MM. Nonselective and selective benzodiazepine receptor agonists: were are we today? Sleep 2000; 23(S1): S39–47PubMed

33.

Wagner J, Wagner ML, Hening WA. Beyond Benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998; 32: 689–91

34.

Holbrook AM, Crowter R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162(2): 225–33PubMedCentralPubMed

35.

Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992; 53(12 Suppl. ): 4–9PubMed

36.

Monti JM, Monti D. Pharmacological treatment of chronic insomnia. CNS Drugs 1995; 4(3): 182–94

37.

Hartmann PM. Drug treatment on insomnia: indications and newer agents. Am Fam Physician 1995; 51(1): 191–4, 197-8PubMed

38.

Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60(2): 413–45PubMed

39.

Albin H, Vincon G, Vincon J, et al. Study of pharmacokinetics of Zolpidem in healthy volunteers after repeated administration: effect of antipyrine clearance. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 369–370

40.

Amrein R, Eckert H, Haefeli H, et al. Pharmacokinetic and clinical considerations in the choice of a hypnotic. Br J Clin Pharmacol 1983; 16: S5S–10

41.

Bailey L, Ward M, Musa MN. Clinical pharmacokinetics of benzodiazepines. J Clin Pharmacol 1994; 34: 804–11PubMed

42.

Flórez J, Hurlé MA. Fármacos ansiolíticos y sedantes. In: Flórez J, Armijo JA, Mediavilla A, editors. Farmacología humana. Edición 2. Barcelona: Masson-Salvat, 1992: 383–397

43.

Greenblatt DJ, Divoll M, Abernethy DR, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinetic 1983; 8: 233–52

44.

Nishino S, Minot E. Drug treatment of patients with insomnia and excessive daytime sleepiness. Clin Pharmacokinet 1999: 37(4): 305–30PubMed

45.

Uchiumi M, Isawa S, Suzuki M, et al.. The Effects of zolpidem and zopiclone on daytime sleepiness and psychomotor per-formance Nihon Shinkei Seishin Yakurigaku Zasshi 2000; 20: 123–30PubMed

46.

Parrino L, Terzano M. Polysomnographic effects of hypnotic drugs: a review. Psychopharmacology 1996; 126(1): 1–16PubMed

47.

Parrino L, Boselli M, Spaggiari MC, et al. Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: polysomnographic analysis by means of the cyclic alternating pattern. Clin Neuropharmacol 1997; 20(3): 253–63PubMed

48.

Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59(4): 865–89PubMed

49.

Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55(2): 277–302PubMed

50.

Vignola A, Lamoureux C, Bastien CH, et al. Effects of chronic insomnia and use of benzodiazepines on daytime performance in older adults. J Gerontol 2000; 55B(1): 54–62

51.

Unden M, Roth T, Schechter B. Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry 1996; 11 Suppl. 1: 21S–30S

52.

Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991; 52 Suppl. 7: 16–23PubMed

53.

Langer SZ, Arbilla S. Limitation of the benzodiazepine receptor nomenclature: a proposal for a pharmacological classification as omega receptors. Fundam Clin Pharmacol 1988; 2: 159–70PubMed

54.

Monti J. Fármacos hipnóticos. En: Flórez J, Armijo JA, Mediavilla A, editors. Farmacología humana. Edición 2. Barcelona: Masson-Salvat, 1992

55.

Arbilla S, Allen J, Wick A, et al. High affinity (3H)-Zolpidem binding in the rat brain: an imidazopyridine agonist properties at central benzodiazepine receptors. Eur J Pharmacol 1986; 130: 257–63PubMed

56.

Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000; 23(1): 17–21PubMed

57.

Soldstes CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999; 14: 287–303

58.

Hajak G, Clarebach P, Fischer W, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 1998; 248(3): 148–56PubMed

59.

Soyka M, Bottlender R, Möller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000; 33: 138–41PubMed

60.

Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: a critical review. J Clin Psychopharmacol 1989; 9: 161–72PubMed

61.

Ware J, Walsh J, Scharf M, et al. Minimal rebound insomnia after treatment with 10mg zolpidem. Clin Neuropharmacol 1997; 20(2): 116–25PubMed

62.

Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association. American Psychiatric Association Press, Washington DC: 1994

63.

Cowen PJ, Nutt DJ. Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism? Lancet 1982; I: 360–2

64.

File SE, Hitchcott PK. A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomena. Psychopharmacology 1990; 101: 525–32PubMed

65.

Gibert-Rahola J, Micó JA. En la farmacodependencia, ¿son iguales todas las benzodiacepinas?.. En: Casas M, Gutiérrez M, San L, editors. Adicción a Psicofarmacos. Monografías de toxicomanías III. Ediciones en Neurociencias: 117-124. Sitges, 1993

66.

Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs 1994; 1: 377–87

67.

Darcourt G, Pringuey D, Salliere D, et al. The safety and tolerability of zolpidem: an update. J Psychopharmacol 1999; 13(1): 81–93PubMed

68.

Uchiumi M, Isawa S, Suzuki M, et al. The effects of zolpidem and zopiclone on daytime sleepiness and psychomotor performance. Nihon Shinkei Seishin Yakurigaku Zasshi 2000; 20(3): 123–30PubMed

69.

Fossen A, Godlibsen OB, Loyning Y. Effects of hypnotics on memory, studies 1 and 2. Pharmacology 1983; 27 Suppl. 2: 116–26PubMed

70.

Hindmarch I. Residual effects of hypnotics: an update. J Clin Psychiatry 1991; 52 Suppl. 7: 14–5PubMed

71.

Bensimon G, Warot D, Foret J, et al. Residual effects of hypnotics: comparative study of zolpidem and flunitrazepam versus placebo. In: sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 374

72.

Harrison C, Subhan Z, Hindmarch I. Residual effects of zopiclone and benzodiazepine hypnotics on psychomotor performance related to car driving. Drugs Exp Clin Res 1985; 11: 823–9PubMed

73.

Subhan Z, Hindmarch I. Effects of zopiclone and benzodiazepine hypnotics on search in short term memory. Neuropsychobiology 1984; 12: 244–8PubMed

74.

George C. Perspectives on the management of insomnia in patients with chronic respiratory Disorders. Sleep 2000; 23 Suppl. 1: S31–5PubMed

75.

Girault C, Muir JF, Mihaltan F, et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest 1996; 110: 1203–11PubMed

76.

Priest R. Modern management of insomnia: with special reference to the cardiovascular patient. Br J Cardiol 1996; 3(5): 136–9

77.

Cirignotta F, Mondini F, Zucconi M, et al. Zolpidempolysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav 1988; 29(4): 807–9PubMed

78.

Steens R, Pouliot Z, Millart T, et al. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993; 16(4): 318–26PubMed

79.

Lofaso F, Goldenberg F, Thebault C, et al. Effect of zopiclone on sleep, night-time ventilation, and daytime vigilance in upper airway resistance syndrome. Eur Respir J 1997; 10(11): 2573–7PubMed

80.

Schwartz S, McDowell W, Cole SR, et al. Insomnia and heart disease: a review of epidemiologic studies. J Psychosom Res 1999; 47(4): 313–33PubMed

81.

Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacological agents for the treatment of insomnia. Ann Pharmacother 1998; 32(6): 680–91PubMed

82.

Sharf MB. Individualizing therapy for early, middle-of-the-night and late-night insomnia. Int J Clin Pract Suppl 2001; 116: 20–4

83.

Hauri P. Insomnia. Clin Chest Med 1998; 19(1): 157–68PubMed

84.

Gillin JC, Byerley WF. The diagnosis and management of insomnia. N Engl J Med 1990; 322: 239–48PubMed

85.

Morin CM, Hauri PJ, Espie CA, et al. Nonpharmacologic treatment of chronic insomnia: an American academy of sleep medicine review. Sleep 1999; 22(8): 1134–56PubMed

86.

Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002 Jun; 180: 528–35PubMed

87.

Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002 Apr; 22(2): 137–47PubMed

88.

Richardson GS. Managing insomnia in the primary care setting: raising the issues. Sleep 2000; 23 Suppl. 1: S9–S12PubMed

89.

Dunner DL. Long-term use of sedative and hypnotic medication [letter]. Arch Gen Psychiatry 1999; 56(4): 355PubMed

90.

Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278(24): 2170–7PubMed

91.

Lader MH. Implications of hypnotic flexibility on patterns of clinical use. Int J Clin Pract Suppl 2001; 116: 14–9PubMed

92.

Ohayon MM, Caulet M, Arbus L, et al. Are prescribed medications effective in the treatment of insomnia complaints? J Psychosom Res 1999; 47(4): 359–68PubMed

93.

Maarek L, Cramer P, Attali P, et al. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992; 20: 162–70PubMed

94.

Scharf M, Mendels J, Thorpy M, et al. Safety of long-term zolpidem treatment in patients with insomnia. Curr Ther Res Clin Exp 1994; 55(9): 1100–11

95.

Roth T. New trends in insomnia management. J Psychopharmacol 1999; 13(4): S37–40PubMed

96.

Cluydts R, Peeters K, de Bouyalsky I. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998; 26(1): 13–24PubMed

97.

Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23(8): 1087–96PubMed

98.

Allain H, Arbus L, Schuck S. Efficacy and safety of zolpidem administered ‘as needed’ in primary insomnia: results of a double blind, placebo-controlled study. Clin Drug Invest 2001; 21: 391–400

99.

Gillin JC, Duncan WH, Murphy DL. Age related changes in sleep in depressed and normal subjects. Psychiatry Res 1981; 4: 73–8PubMed

100.

Avidan AY. Sleep changes and disorders in the elderly patient. Curr Neurol Neurosci Rep 2002; 2(2): 178–85PubMed

101.

Schneider DL. Insomnia: safe and effective therapy for sleep problems in the older patient. Geriatrics 2002 May; 57(5): 24–6, 29-32PubMed

102.

Finucane TE. Treatment for insomnia. Lancet 2002 Apr 20; 359(9315): 1434PubMed

103.

Wittchen HU, Krause P, Hofler M, et al. NISAS-2000: The Nationwide Insomnia Screening and Awareness Study: prevalence and interventions in primary care. Fortschr Med Orig 2001; 119(1): 9–19PubMed

104.

Ramesh M, Roberts G. Use of night-time benzodiazepines in an elderly inpatient population. J Clin Pharm Ther 2002; 2: 93–7

105.

Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002; 11(2): 97–104PubMed

106.

Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50(1): 26–34PubMed

107.

Roehrs T, Roth T. Hypnotics: efficacy and adverse effects. In Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000

108.

Higbee MD, Plaza CM, Dunkelbarger-Reed J. Understanding and managing sleep difficulties in the elderly. J Pharm Pract 2000; 13(4): 316–26

109.

Leger D, Scheuermaier K, Roger M. The relationship between alertness and sleep in a population of 769 elderly insomniacs with and without treatment with zolpidem. Arch Gerontol Geriatr 1999; 29(2): 165–73PubMed

110.

FDA. Drug Pregnancy Categories. http://depts.washington/edu/druginfo/formulary/pregnancy.pd

111.

Estivill E, De-la-Fuente V, Barraquer A. Pharmacological treatment of insomnia in children with neurological disorders. Rev Neurol 1997; 25(146): 1617–20PubMed

112.

Krystal AD, Edinger J, Wohlgemuth W, et al. Sleep in peri-menopausal and post-menopausal women. Sleep Med Rev 1998; 2(4): 243–53PubMed

113.

Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4(1): 31–47PubMed

114.

Montplaisir J, Lorrain J, Denesle R, et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001; 8(1): 10–6PubMed

115.

Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992; 53 Suppl. : 4–7PubMed

116.

Thase ME. Treatment issues related to sleep and depression. J Clin Psychiatry 2000; 61 Suppl. 11: 46–50PubMed

117.

Asnis G, Chakraburtty A, Duboff E, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60(10): 668–76PubMed

118.

Fussel A, Wolf A, Brattstrom A. Effect of a fixed valerian-Hop extract combination (Ze 91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res 2000; 5(9): 385–90PubMed

119.

Dominguez RA, Bravo-Valverde RL, Kaplowitz BR, et al. Valerian as a hypnotic for Hispanic patients. Cultur Divers Ethni Minor Psychol 2000; 6(1): 84–92

120.

Richardson G, Tate B. Hormonal and pharmacological manipulation of the circadian clock: recent developments and future strategies. Sleep 2000; 23 Suppl. 3: S77–85PubMed

121.

Nowell PD, Reynolds3rd CF, Buysse DJ, et al. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999; 60(2): 89–95PubMed

122.

Neylan TC, Metzler TJ, Schoenfeld FB, et al. Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress 2001 Jul; 14(3): 461–7PubMed

123.

Silvestri R, Pace-Schott EF, Gersh T, et al. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry 2001 Aug; 62(8): 642–52PubMed

124.

Winokur A, Gary KA, Rodner S, et al. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001; 14(1): 19–28PubMed

125.

Pace-Schott EF, Gersh T, Silvestri R, et al. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001 Jun; 10(2): 129–42PubMed

126.

Leger D. Public health and insomnia: economic impact. Sleep 2000; 23 Suppl. 3: S69–76PubMed

127.

Allain H, Gibert Rahola J. Switching to zolpidem in patients habituated to long-term benzodiazepine use. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Elsevier, Paris 1996: 175–182

128.

Allain H, LeCoz F, Borderies P, et al. Use of zolpidem 10mg as a benzodiazepine substitute in 84 patients with insomnia. Hum Psychopharmacol 1998; 13: 551–9

Title: Consensus on Drug Treatment, Definition and Diagnosis for Insomnia
Authors: Dr E. Estivill
A. Bové
D. García-Borreguero
J. Gibert
J. Paniagua
G. Pin
F. J. Puertas
R. Cilveti
Publication date: 01-06-2003
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 6/2003
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200323060-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Consensus on Drug Treatment, Definition and Diagnosis for Insomnia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2003

RETRACTED ARTICLE: Prevention of Nausea and Vomiting with Ramosetron after Total Hip Replacement

Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers

Salivary Flow Rates and Pharmacokinetics in Healthy Japanese and Caucasian Volunteers Administered Oral Pilocarpine

Dermatomycoses of the Glabrous Skin